

[Open Peer Review on Qeios](#)

Anti-PD1/Anti-CTLA4 Antibody Mixture PSB205

National Cancer Institute

Source

National Cancer Institute. *Anti-PD1/Anti-CTLA4 Antibody Mixture PSB205*. NCI Thesaurus. Code C162774.

A mixture of two engineered monoclonal antibodies produced by a single cell line of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/anti-CTLA4 antibody mixture PSB205 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.